Published in Pharmacotherapy on April 01, 2001
Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis (2016) 2.32
Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85
New developments in aminoglycoside therapy and ototoxicity. Hear Res (2011) 1.35
How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? BMC Infect Dis (2014) 0.95
Overview of therapeutic drug monitoring. Korean J Intern Med (2009) 0.94
Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother (2011) 0.91
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol (2015) 0.84
Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. Int J Antimicrob Agents (2013) 0.82
Section 4: Contrast-induced AKI. Kidney Int Suppl (2011) (2012) 0.82
Standard operating procedures for antibiotic therapy and the occurrence of acute kidney injury: a prospective, clinical, non-interventional, observational study. Crit Care (2014) 0.78
Section 3: Prevention and Treatment of AKI. Kidney Int Suppl (2011) (2012) 0.78
Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. J Antimicrob Chemother (2016) 0.78
Outcomes in patients with gram-negative sepsis treated with gentamicin. Ther Adv Drug Saf (2012) 0.75
Validity of cardiovascular disease risk factors assessed by telephone survey: the Behavioral Risk Factor Survey. J Clin Epidemiol (1993) 2.91
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics (2000) 2.17
Reliability and changes in validity of self-reported cardiovascular disease risk factors using dual response: the behavioral risk factor survey. J Clin Epidemiol (1996) 2.11
Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis (1993) 2.10
Relative abundance of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women in Long Island, New York. Cancer Epidemiol Biomarkers Prev (1998) 1.77
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.77
Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? Clin Infect Dis (1998) 1.52
Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med (2000) 1.21
Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother (1997) 1.20
Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother (1995) 1.15
Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin Pharmacol Ther (2000) 1.12
The absolute bioavailability of oral melatonin. J Clin Pharmacol (2000) 1.09
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother (2006) 1.01
Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther (1998) 0.99
Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother (1997) 0.98
Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet (1998) 0.96
Self-reported physical activity in a rural county: a New York county health census. Am J Public Health (1994) 0.96
Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother (1998) 0.95
Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses. Antimicrob Agents Chemother (1994) 0.93
Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism. Am Heart J (1992) 0.92
Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother (1999) 0.91
Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers. Antimicrob Agents Chemother (1996) 0.91
Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol (2001) 0.87
Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics (1998) 0.87
Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother (1998) 0.86
A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy. J Clin Pharmacol (2001) 0.85
Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther (1998) 0.85
Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother (1992) 0.84
Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol (1991) 0.83
Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet (1994) 0.83
Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther (2007) 0.83
A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J Clin Pharmacol (2000) 0.83
Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. Pharmacogenetics (2001) 0.82
Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J Lab Clin Med (1993) 0.82
Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther (1998) 0.82
Oral cimetidine prolongs clarithromycin absorption. Antimicrob Agents Chemother (1998) 0.80
Is it sex or is it gender? Clin Pharmacol Ther (2000) 0.80
Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrob Agents Chemother (1999) 0.79
Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe. Int J Clin Pharmacol Ther (2009) 0.79
Different outcomes for different interventions with different focus!--A cross-country comparison of community interventions in rural Swedish and US populations. Scand J Public Health Suppl (2001) 0.79
Distribution of orthopaedic surgeons, lawyers, and malpractice claims in New York. Clin Orthop Relat Res (1997) 0.78
Diagnosis and treatment of complicated tubercular meningitis. Pharmacotherapy (1999) 0.76
Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteers. J Antimicrob Chemother (1999) 0.76
Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther (1999) 0.75
Lack of effect of atenolol and nadolol on the metabolism of theophylline. Br J Clin Pharmacol (1990) 0.75
Simple liquid chromatographic method for the analysis of the blood brain barrier permeability characteristics of ceftriaxone in an experimental rabbit meningitis model. J Chromatogr B Biomed Sci Appl (1999) 0.75
Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents. Antimicrob Agents Chemother (1996) 0.75
Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias. Drug Intell Clin Pharm (1988) 0.75
Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother (1998) 0.75
A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. Am J Med (1999) 0.75
Menstrual cycle and renal clearance. Clin Pharmacol Ther (1991) 0.75
The Norsjö-Cooperstown healthy heart project: a case study combining data from different studies without the use of meta-analysis. Scand J Public Health Suppl (2001) 0.75
Potential influence of timing of low-density lipoprotein cholesterol evaluation in patients with acute coronary syndrome. Pharmacotherapy (2001) 0.75
Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. DICP (1991) 0.75
Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase. J Clin Pharmacol (1998) 0.75
Impact of food on the bioavailability of encainide. J Clin Pharmacol (1992) 0.75
Economic aspects of pharmacokinetic services. Pharmacoeconomics (1993) 0.75
Comparative pharmacodynamics of intravenous lidocaine in patients with acute and chronic ventricular arrhythmias. Ann Pharmacother (1992) 0.75
Lidocaine-induced second-degree mobitz type II heart block. Drug Intell Clin Pharm (1985) 0.75
Effect of seven fluoroquinolones on the determination of serum creatinine by the picric acid and enzymatic methods. Ann Pharmacother (1993) 0.75
Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics (1999) 0.75
Omeprazole: a comprehensive review. Pharmacotherapy (1993) 0.75